infect
virus
hijack
variou
host
cell
compon
program
amplif
among
canon
erk
signal
pathway
mainli
consist
three
tier
serinethreonin
kinas
raf
mek
erk
two
isoform
kinas
oper
immedi
upstream
erk
connect
raf
erk
phosphoryl
erk
previou
studi
suggest
differ
isoform
mek
distinct
biolog
function
although
vitro
kinas
function
may
redund
howev
littl
known
isoformspecif
effect
kinas
viral
propag
studi
show
herp
simplex
viru
type
infect
human
embryon
kidney
hek
cell
induc
sustain
activ
inhibit
erk
activ
specif
inhibitor
sever
impair
viru
product
similar
reduct
viru
product
also
seen
follow
transfect
cell
sirna
interestingli
specif
knockdown
sirna
caus
mark
inhibit
viral
titer
viral
protein
virusinduc
cytopath
effect
cpe
wherea
silenc
littl
effect
therefor
result
demonstr
act
differ
hijack
host
amplif
knowledg
first
report
show
inhibit
replic
target
human
studi
also
suggest
could
potenti
target
therapi
may
minim
damag
host
cell
engend
target
human
herp
simplex
viru
type
belong
alpha
herpesviru
subfamili
gene
divid
three
broad
group
term
immediateearli
ie
alpha
gene
earli
beta
gene
late
gamma
gene
accord
tempor
order
express
requir
express
viral
product
hay
ruyechan
wagner
et
al
ward
roizman
character
short
cytolyt
replic
cycl
permiss
cell
abil
establish
latenc
sensori
ganglia
brook
et
al
weir
whitley
account
new
genit
infect
caus
mainli
herp
lesion
extern
area
genit
organ
brook
et
al
sizemor
et
al
also
common
caus
neonat
herp
hill
robert
yamashita
morishima
overal
infect
produc
strong
morbid
show
broad
preval
long
latenc
difficult
curabl
date
prevent
vaccin
effect
therapeut
drug
recurr
infect
avail
extracellular
signal
regul
kinas
erk
cascad
one
three
major
mitogenactiv
protein
kinas
mapk
cascad
consist
three
tier
serinethreonin
kinas
raf
mapkerk
mek
erk
chang
et
al
cohen
mccubrey
et
al
zhang
liu
raf
consist
three
isoform
braf
araf
activ
partner
mek
substrat
mek
erk
ie
found
date
chambard
et
al
thu
second
kinas
compris
two
isoform
play
key
role
connect
raf
erk
inhibit
mek
studi
effect
way
investig
import
rafmekerk
signal
cascad
variou
cellular
physiolog
patholog
process
kelemen
et
al
kohno
pouyssegur
luo
et
al
mccubrey
et
al
shakibaei
et
al
yipschneid
schmidt
zheng
et
al
mani
scenario
function
interchang
howev
recent
studi
ad
complex
signal
function
term
interact
activ
substrat
respons
extracellular
factor
variou
cellular
function
regul
belang
et
al
skarpen
et
al
ussar
voss
exampl
ident
found
ntermin
region
mek
contain
characterist
prolinerich
insert
involv
interact
activ
substrat
enslen
davi
kolch
form
signal
complex
suggest
cell
signal
pathway
preferenti
activ
erk
via
jelinek
et
al
furthermor
distinct
way
regul
erk
activ
cell
cycl
progress
ussar
voss
addit
differ
phenotyp
demonstr
knockout
mice
belang
et
al
giroux
et
al
studi
indic
exhibit
differ
biolog
function
virus
ultim
depend
host
cell
replic
take
advantag
preexist
signal
pathway
host
cell
amplif
surviv
numer
studi
demonstr
activ
rafmekmapk
pathway
specif
respons
viru
infect
play
import
role
viru
replic
cai
et
al
jacqu
et
al
king
et
al
ludwig
et
al
luo
et
al
panteva
et
al
pleschka
et
al
smith
et
al
exampl
specif
inhibitor
shown
sever
impair
growth
varieti
virus
cultur
cell
model
cai
et
al
jacqu
et
al
ludwig
et
al
planz
et
al
pleschka
et
al
smith
et
al
howev
specif
contribut
viru
replic
knowledg
address
date
present
studi
rnai
technolog
use
specif
silenc
express
hek
cell
effect
subsequ
replic
assess
antibodi
purchas
cell
signal
bd
bioscienc
sigma
east
coast
bio
hsv
gb
monoclon
antibodi
hsv
monoclon
antibodi
kind
gift
dr
roger
everett
univers
glasgow
human
embryon
kidney
hek
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
heatinactiv
fetal
bovin
serum
fb
hyclon
co
humidifi
incub
hek
cell
infect
strain
kindli
provid
dr
wx
jia
differ
multipl
infect
moi
indic
figur
legend
h
inoculum
remov
incub
continu
dmem
contain
fb
viral
growth
supernat
collect
differ
time
postinfect
pi
clarifi
centrifug
g
viral
titer
determin
plaqu
assay
carri
triplic
specif
short
interf
rna
sirna
target
sequenc
human
mrna
select
base
previou
report
ussar
voss
mutant
sirna
deriv
target
sequenc
contain
base
pair
substitut
near
end
tabl
use
control
sirna
use
commerci
synthes
gene
chem
ltd
list
tabl
altern
sirna
santa
cruz
consist
pool
threefiv
targetspecif
nt
sirna
human
mrna
use
confirm
effect
seen
replic
hek
cell
transfect
well
plate
confluenc
sirna
concentr
nm
use
interf
polyplustransfect
accord
manufactur
instruct
cell
maintain
growth
medium
h
chang
medium
contain
fb
h
infect
moi
follow
viru
adsorpt
h
dmem
supplement
fb
ad
incub
continu
select
time
viru
titer
medium
h
pi
measur
plaqu
assay
cell
lysat
infect
use
western
blot
analysi
earli
viral
protein
late
protein
gb
host
cellular
protein
provid
posit
control
inhibit
inhibitor
specif
inhibitor
promega
freshli
dissolv
mm
dmso
ad
cultur
medium
final
concentr
h
throughout
entir
period
infect
hek
cell
examin
follow
infect
everi
h
interv
postinfect
cytopath
effect
cpe
use
phasecontrast
microscopi
cell
lyse
buffer
contain
mm
hepe
ph
mm
nacl
mm
edta
ph
mm
na
vo
mm
naf
glycerol
sd
triton
mm
pnitrophenylphosph
mm
glycerophosph
supplement
complet
proteas
inhibitor
roch
cell
lysat
obtain
centrifug
rpm
protein
concentr
determin
bicinchonin
acid
protein
assay
kit
pierc
protein
resolv
onto
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
transfer
pvdf
membran
millipor
membran
blot
specif
primari
antibodi
indic
figur
legend
follow
incub
secondari
antibodi
conjug
horseradish
peroxidas
develop
enhanc
chemiluminesc
substrat
ecl
supersign
west
femto
maximum
sensit
substrat
pierc
rel
amount
normal
densitometr
scan
actin
use
band
leader
softwar
version
statist
differ
analysi
level
viral
titer
pfuml
carri
use
anova
determin
erk
activ
hek
cell
infect
cell
extract
blot
antibodi
shown
fig
erk
activ
peak
around
h
sustain
h
follow
infect
activ
sever
suppress
presenc
mekspecif
inhibitor
assess
contribut
erk
activ
replic
ad
cultur
medium
prior
infect
shown
fig
propag
increas
progress
significantli
diminish
treatment
inhibitori
effect
last
h
result
suggest
activ
rafmekerk
cascad
necessari
replic
consist
studi
also
show
similar
inhibit
ad
h
postinfect
data
shown
confirm
result
mek
inhibitor
transfect
sirna
specif
examin
effect
viru
product
shown
fig
express
diminish
h
posttransfect
dosedepend
manner
silenc
effect
specif
crosssilenc
sirna
observ
fig
e
mutat
sirna
mu
base
pair
replac
tabl
addit
express
affect
cotransfect
fig
b
titrat
experi
found
evid
cell
toxic
even
nm
sirna
achiev
maxim
knockdown
effect
data
shown
control
cell
mock
infect
basal
phosphoryl
inhibit
fig
virusinfect
cell
activ
reduc
transfect
nm
respect
fig
p
anova
measur
gb
protein
express
viru
titer
shown
fig
express
two
viral
protein
significantli
reduc
concurr
replic
measur
plaqu
assay
inhibit
rang
compar
viral
titer
seen
transfect
cell
fig
p
taken
togeth
result
indic
infect
induc
activ
host
erk
pathway
turn
use
viru
replic
determin
isoformspecif
effect
mek
erk
activ
hek
cell
transfect
respect
infect
shown
fig
transfect
effect
silenc
express
dosedepend
manner
furthermor
mockinfect
cell
reduc
express
significantli
alter
erk
phosphoryl
basal
level
fig
e
wherea
reduc
express
led
inhibit
phosphoryl
compar
respect
mock
transfect
group
fig
e
moreov
virusinfect
cell
erk
activ
diminish
degre
sirna
two
respect
mek
compar
cognat
mutat
sirna
fig
e
p
anova
addit
ident
result
erk
inhibit
obtain
altern
sirna
design
differ
sequenc
segment
data
shown
henc
data
point
distinct
function
erk
activ
mockand
virusinfect
cell
investig
whether
two
mek
subtyp
act
differ
replic
cell
transfect
infect
compar
control
cell
infect
alon
transfect
specif
inhibitor
viru
product
examin
fig
shown
cell
transfect
nm
titer
markedli
inhibit
compar
treat
cell
p
anova
signific
differ
cell
treat
p
anova
contrast
transfect
display
signific
effect
consist
knockdown
result
clear
reduct
gb
protein
express
fig
knockdown
show
chang
gb
protein
level
fig
similar
result
obtain
altern
sirna
data
shown
thu
result
demonstr
play
import
role
amplif
although
activ
contribut
erk
activ
viru
infect
determin
effect
cytopath
effect
cpe
cell
transfect
infect
fig
monitor
phasecontrast
microscopi
everi
h
day
pi
experi
mock
infect
infect
transfect
use
control
h
pi
cell
transfect
nm
nm
manifest
much
less
cpe
compar
control
note
cell
pretreat
show
obviou
sign
cpe
similarli
result
cpe
shown
use
altern
sirna
data
shown
result
indic
requir
cpe
jacqu
et
al
king
et
al
ludwig
et
al
luo
et
al
panteva
et
al
planz
et
al
pleschka
et
al
smith
et
al
case
seen
neuron
nonneuron
cell
hunter
et
al
perkin
et
al
smith
et
al
studi
usual
made
use
two
chemic
inhibitor
block
activ
erk
cascad
kelemen
et
al
planz
et
al
pleschka
et
al
sturgil
howev
inhibitor
limit
exampl
may
produc
offtarget
effect
importantli
unabl
distinguish
effect
mediat
circumv
limit
allow
distinct
individu
involv
viru
replic
studi
made
use
rna
interfer
knock
express
individu
mek
isoform
thu
demonstr
express
viral
protein
viral
dna
polymeras
envelop
glycoprotein
gb
yield
infecti
viru
cpe
markedli
decreas
erk
activ
block
pretreat
cell
either
mek
sirna
fig
c
consist
previou
find
use
chemic
inhibitor
perkin
et
al
smith
et
al
furthermor
result
shown
activ
erk
play
essenti
role
viral
product
wherea
dispens
although
latter
also
contribut
virusinduc
erk
activ
fig
knowledg
first
report
activ
rather
isoform
import
replic
find
add
new
inform
understand
host
cell
erk
signal
pathway
util
viru
also
provid
new
evid
isoformspecif
function
mek
viru
propag
thu
far
remain
unclear
infect
caus
activ
erk
smith
et
al
smith
et
al
report
infect
induc
express
pk
larg
subunit
ribonucleotid
reductas
intrins
protein
kinas
activ
turn
found
lead
increas
rasgtp
subsequ
activ
lie
immedi
upstream
erk
signal
cascad
howev
studi
provid
clue
requir
viru
product
despit
activ
viru
infect
possibl
complex
may
associ
either
compon
necessari
viru
replic
relev
possibl
earlier
studi
shown
form
signal
complex
jelinek
et
al
mek
erk
form
complex
togeth
scaffold
protein
appar
prefer
morrison
davi
schaeffer
et
al
clearli
futur
studi
requir
unravel
detail
molecular
event
link
activ
erk
signal
cascad
involv
effect
growth
virusinfect
cell
attempt
explor
possibl
therapi
viral
infect
cellular
protein
import
viru
life
cycl
consid
also
noteworthi
mani
small
molecular
compound
inhibit
mapk
pathway
inhibitor
reach
clinic
trial
stage
cancer
therapi
english
cobb
kohno
pouyssegur
data
add
new
inform
consid
potenti
antivir
molecular
target
may
safer
fewer
side
effect
produc
target
target
two
conclus
studi
first
identifi
key
role
play
mek
activ
erk
signal
cascad
requir
maxim
replic
viral
infect
cell
find
rais
possibl
identif
specif
small
molecul
inhibitor
kinas
lead
develop
new
class
antivir
combat
diseas
clearli
studi
need
fulli
character
benefit
limit
block
base
activ
erk
pathway
diseas
depend
viru
product
erk
activ
hek
cell
preincub
without
h
follow
infect
moi
cell
medium
collect
separ
differ
time
point
cell
lysat
blot
antibodi
antibodi
b
viru
titer
medium
measur
plaqu
assay
data
shown
mean
standard
deviat
n
titer
yaxi
repres
logarithm
valu
valu
obtain
significantli
differ
absenc
indic
asterisk
p
anova
e
cell
transfect
specif
sirna
wt
mutat
version
mu
indic
blot
antibodi
indic
result
show
specif
knockdown
crosssilenc
effect
repres
one
triplic
experi
serv
load
control
transfect
effici
current
studi
evalu
transfect
gfp
sirna
data
shown
experi
perform
panel
b
except
use
examin
effect
erk
activ
n
use
load
control
e
quantif
band
h
pi
rel
band
panel
b
fig
panel
ad
figur
determin
densitometr
scan
rel
intens
yaxi
present
percentag
intens
mock
transfect
data
averag
three
independ
experi
error
bar
denot
standard
deviat
p
versu
nm
anova
knockdown
differenti
impact
replic
cell
transient
transfect
dose
indic
respect
cell
transfect
serv
neg
control
treat
h
throughout
entir
period
posit
control
cell
infect
moi
h
posttransfect
cultur
supernat
cell
collect
h
pi
supernat
assay
viral
titer
pfuml
data
repres
averag
three
independ
experi
shown
mean
standard
deviat
n
p
compar
nm
anova
b
c
protein
lysat
b
c
transfect
cell
blot
antihsv
gb
monoclon
antibodi
detect
viral
protein
express
data
one
repres
three
independ
experi
cpe
induc
hek
cell
cell
transfect
combin
indic
dose
infect
h
posttransfect
moi
effect
mek
sirna
cpe
examin
h
pi
imag
taken
h
pi
oppos
cell
mock
infect
infect
control
control
sirna
target
sequenc
sens
strand
studi
